Albuterol - Control
PreclinicalSmall molecule
Albuterol - Control is one of 10 small molecule programs targeting Wheezing. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Wheezing
#DrugCompanyPhaseTrials
1Flovent
PParatek Pharmaceuticals Inc
Approved
Spiriva
Boehringer IngelheimApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
Prednisolone Sodium Phosphate
UUniversity of Oulu
Phase 3
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Resveratrol
NNational Cancer Institute (NCI)
Preclinical
Inhaled Albuterol
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Albuterol - Control
UUniversity of Sao Paulo
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Albuterol - Control. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Sao Paulo